Streetbeat News

TSVT

2seventy bio, Inc.

https://www.2seventybio.com

Industry

Biotechnology

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Open

4.95

Mkt cap

255M

Volume

High

4.96

P/E Ratio

-2.70

52-wk high

5.99

Low

4.94

Div yield

N/A

52-wk low

2.29

During Wednesday's trading, 103 companies set new 52-week lows. The biggest company in terms of market cap to set a new 52-week low was Estee Lauder Cos (NYSE:EL), while the smallest was Esports Entertainment (NASDAQ:GMBL). ExlService Holdings (NASDAQ:EXLS)'s stock moved significantly downwards, trading down 80.66% to reach a new 52-week low. IDT (NYSE:IDT) saw the biggest bounce back, as shares traded up 0.04% to rebound after it hit its new 52-week low.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 11:53 am

On Tuesday, 46 stocks hit new 52-week lows. The largest company by market cap to hit a new 52-week low was Moderna (NASDAQ:MRNA). The smallest firm by market cap to set a new 52-week low was American Rebel Holdings (NASDAQ:AREB). Polished.com (AMEX:POL) made the largest move down on the session, with shares plummeting 66.66% to reach its 52-week low. Brera Holdings (NASDAQ:BREA)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:08 am

Wedbush analyst David Nierengarten has maintained an Outperform rating on 2seventy bio (NASDAQ:TSVT), but lowered the price target from $26 to $22.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 5:54 pm

During Friday's session, 59 companies set new 52-week lows. The largest firm by market cap to set a new low was Bristol-Myers Squibb (NYSE:BMY), while the smallest was BitNile Metaverse (NASDAQ:BNMV). Tonix Pharmaceuticals (NASDAQ:TNXP) saw the largest move with shares plummeting 38.2%. ClearPoint Neuro (NASDAQ:CLPT)'s stock bounced back the most, rising 0.0% after reaching its new low.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 4:36 pm

In the last quarter, 2seventy bio (NASDAQ:TSVT) received three somewhat bullish ratings and one indifferent rating from analysts. The company's average price target is $22.5, a decrease of 15.09% from the previous average price target of $26.50.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 2:01 pm

Morgan Stanley analyst Matthew Harrison has downgraded 2seventy bio (NASDAQ:TSVT) from Overweight to Equal-Weight and lowered the price target from $25 to $13.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:31 am

Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

July 20, 2023 | 1:08 pm

The FDA has placed a clinical hold on Arcellx Inc's (NASDAQ:ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA, a drug for relapsed or refractory multiple myeloma, following a recent patient death. Arcellx is working with the FDA to amend the protocol. Kite, a Gilead Sciences Inc (NASDAQ:GILD) company, announced a collaboration with Arcellx in December 2022 to co-develop and co-commercialize CART-ddBCMA.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 12:19 pm

Clinical trials for cancer treatments conducted by 2seventy bio (NASDAQ:TSVT) and Mersana (NASDAQ:MRSN) have been halted after the deaths of six participants. TSVT's trial focused on acute myeloid leukemia, while MRSN's trial targeted ovarian cancer.

Portfolio Pulse from Bibhu Pattnaik

June 17, 2023 | 8:37 pm

2seventy Bio's Phase 1 trial of SC-DARIC33 in Acute Myeloid Leukemia (AML) has been paused by Seattle Children's after a fatal serious adverse event (SAE). The root cause of the SAE and its potential relationship to the study drug is under investigation. TSVT shares are down 11.90%.

Portfolio Pulse from Vandana Singh

June 14, 2023 | 2:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.